ArticleThe American journal of bioethics : AJOB2016
An Ethical Exploration of Barriers to Research on Controlled Drugs.
Article in The American journal of bioethics : AJOB, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.Psychological medicine · 2025Article
- Cue-induced Magnetic Resonance Spectroscopy of Glutamate in Addiction Research: Current Evidence, Pros, and Cons.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Review
- Medical Use, Decriminalization, and Legalization of Narcotic Drugs and Psychotropic Substances-What Does It Mean and What Is Its Current Status in India?Indian journal of psychological medicine · 2023Article
- Review
- Healthcare professionals' perspectives on the use of medicinal cannabis to manage chronic pain: A systematic search and narrative review.Pain practice : the official journal of World Institute of Pain · 2022Review
- Article
- Occupational Safety and Health and Illicit Opioids: State of the Research on Protecting Against the Threat of Occupational Exposure.New solutions : a journal of environmental and occupational health policy : NS · 2021Article
- The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness.Frontiers in psychiatry · 2021Article
- Feeding Behaviors in Infants With Prenatal Opioid Exposure: An Integrative Review.Advances in neonatal care : official journal of the National Association of Neonatal Nurses · 2020Review
- A Comparison of Ketamine or Etomidate Combined with Xylazine for Intraperitoneal Anesthesia in Four Mouse Strains.Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Interpol review of controlled substances 2016-2019.Forensic science international. Synergy · 2020Review
- Rodent ketamine depression-related research: Finding patterns in a literature of variability.Behavioural brain research · 2019Review
- Research ethics aspects of experimentation with LSD on human subjects: a historical and ethical review.Medicine, health care, and philosophy · 2019Article
- The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?Frontiers in pharmacology · 2019Review
- The case for medicinal cannabis.Irish journal of medical science · 2018Article
- Cannabis shenanigans: advocating for the restoration of an effective treatment of pain following spinal cord injury.Spinal cord series and cases · 2018Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
We examine the ethical, social, and regulatory barriers that may hinder research on therapeutic potential of certain controversial controlled substances like marijuana, heroin, or ketamine. Hazards for individuals and society and potential adverse effects on communities may be good reasons for limiting access and justify careful monitoring of these substances. Overly strict regulations, fear of legal consequences, stigma associated with abuse and populations using illicit drugs, and lack of funding may, however, limit research on their considerable therapeutic potential. We review the surprisingly sparse literature and address the particular ethical concerns pertinent to research with illicit and addictive substances, such as undue inducement, informed consent, therapeutic misconception, and risk to participants, researchers, and institutions. We consider the perspectives of key research stakeholders and explore whether they may be infected with bias. We conclude by proposing an empirical research agenda to provide an evidentiary basis for ethical reasoning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.